Epstein-Barr virus (EBV) is associated with nasopharyngeal carcinoma (NPC) and provides a potential target for dendritic cell vaccine therapy. This phase 1 clinical study led by Prof Goh Boon Cher and A/Prof Herbert Schwarz indicates that a novel type of dendritic cells pulsed with EBV nuclear antigen LMP2 are safe and exhibits promising efficacy when administered following chemotherapy in patients with locally recurrent or metastatic NPC.

Link to website: https://bit.ly/30fD4Gg